Intra-Cellular Therapies Stock Price, News & Analysis

Intra-Cellular Therapies (Nasdaq: ITCI) will host a virtual event on October 20, 2021, from 12:30 to 3:30 p.m. ET. The event will focus on the company’s pipeline, including lumateperone, ITI-1284, PDE1 inhibitors, and ITI-333. Presentations will be made by management and key opinion leaders. Interested parties can access the live and archived webcast via the Investor Relations section of the company's website. This event aims to provide insights into the innovative treatments being developed for CNS disorders.

Intra-Cellular Therapies announced positive results from its Phase 3 trial for lumateperone (42 mg) in treating major depressive episodes linked to bipolar I and II disorders. The study, involving 381 patients, indicated a significant reduction in depressive symptoms compared to placebo (MADRS score difference -4.6, P<0.0001). Lumateperone demonstrated a favorable safety profile, with adverse events similar to placebo. These findings support the drug's supplemental NDA currently under FDA review, with a target action date of December 17, 2021, positioning lumateperone as a potential new treatment for bipolar depression.

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) announced that CEO Sharon Mates, Ph.D., will present at the 2021 Cantor Virtual Global Healthcare Conference on September 28, 2021, at 10:40 am ET. Investors can access the live and archived webcast in the Investor Relations section of the company's website. Intra-Cellular Therapies focuses on developing therapeutics for central nervous system disorders, leveraging groundbreaking research to create innovative treatments for complex psychiatric and neurologic diseases.

Intra-Cellular Therapies highlights favorable findings from recent studies on lenrispodun (ITI-214), a PDE1 inhibitor, published in several medical journals. These studies indicate lenrispodun is well-tolerated in heart failure patients, enhances cardiac contractility, and improves vascular function in aging models. The research suggests lenrispodun may offer a safer alternative for heart failure treatment by increasing cAMP and cGMP levels. Its potential spans various diseases, including Parkinson's. The promising results could be significant for future clinical applications and therapies.

Intra-Cellular Therapies, a biopharmaceutical company focused on CNS disorders, announced that CEO Sharon Mates, Ph.D., will present at the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021, at 2:30 pm PT. The event will be available via live and archived webcast on the company's website. Intra-Cellular Therapies is known for its innovative approaches in developing treatments for psychiatric and neurologic diseases rooted in Nobel prize-winning research.

Intra-Cellular Therapies (ITCI) reported strong second-quarter results, achieving total revenues of $20 million, a significant increase from $1.9 million year-over-year. Net product revenues for CAPLYTA rose to $19 million, up 22% from the prior quarter. The company is awaiting FDA action on its supplemental new drug applications (sNDAs) for bipolar depression, with a target date of December 17, 2021. The enrollment for the Phase 3 clinical trial of lumateperone as an adjunctive treatment for major depressive disorder has begun. However, the net loss for the quarter was $68.7 million.

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) will host a conference call on August 9, 2021, at 8:30 a.m. ET to discuss its financial results for Q2 2021. The call can be accessed via phone or online, with a specific conference ID provided. The company specializes in developing treatments for CNS disorders based on Nobel Prize-winning research.

Intra-Cellular Therapies (Nasdaq: ITCI) announced the publication of a pooled analysis evaluating the safety and tolerability of lumateperone (42 mg), a treatment for schizophrenia. The analysis included 1,073 patients across three randomized, double-blind, placebo-controlled trials. Findings indicate that lumateperone's safety profile is comparable to placebo, with treatment-emergent adverse events (TEAEs) similar in incidence. Notable outcomes include low discontinuation rates due to TEAEs (0.5%) and minimal changes in weight and metabolic parameters. The publication highlights lumateperone as a favorable treatment for schizophrenia.

Intra-Cellular Therapies, a biopharmaceutical company focused on CNS disorders, announced that Dr. Sharon Mates, CEO and Chairman, will present at two investor conferences. The first is the Jefferies Virtual Healthcare Conference on June 2 at 11:30 am ET, followed by the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10 at 1:20 pm ET. Live and archived webcasts will be available on the company’s website. Intra-Cellular leverages Nobel prize-winning research to develop treatments for complex psychiatric and neurologic diseases.